diazepam - Profile

What are the generic sources for diazepam and what is the scope of patent protection?

Diazepam is the generic ingredient in nine branded drugs marketed by Roche, Chartwell Molecular, Hikma, Bausch, Navinta Llc, Novel Labs Inc, Abraxis Pharm, Alembic, Dr Reddys, Fresenius Kabi Usa, Galenicum Hlth, Hospira, Long Grove Pharms, Marsam Pharms Llc, Parenta Pharms, Regcon Holdings, Us Army, Warner Chilcott, Watson Labs, Watson Labs Inc, Pharmacia And Upjohn, Neurelis Inc, Actavis Elizabeth, Aurobindo Pharma Ltd, Barr, Chartwell Rx, Dr Reddys Labs Sa, Duramed Pharms Barr, Ferndale Labs, Halsey, Ivax Sub Teva Pharms, Martec Usa Llc, Mylan, Nuvo Pharm, Ph Health, Pioneer Pharms, Roxane, Strides Pharma Intl, Teva Pharms, Virtus, Quantum Pharmics, and Waylis Therap, and is included in ninety-three NDAs. There are eight patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Diazepam has thirty-eight patent family members in thirteen countries.

There are three tentative approvals for this compound.

Summary for diazepam

International Patents:	38
US Patents:	8
Tradenames:	9
Applicants:	42
NDAs:	93
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for diazepam

Generic filers with tentative approvals for DIAZEPAM

Applicant	Application No.	Strength	Dosage Form
		7.5MG	FILM;BUCCAL
		5MG	FILM;BUCCAL
		20MG	FILM;BUCCAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DIAZEPAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VALTOCO	Nasal Spray	diazepam	5 mg/spray and 7.5 mg/spray	211635	1	2025-04-03
VALTOCO	Nasal Spray	diazepam	10 mg/spray	211635	1	2024-02-14
DIASTAT ACUDIAL	Rectal Gel	diazepam	5 mg/mL, 2mL pre-filled syringe	020648	1	2008-12-23
DIASTAT ACUDIAL	Rectal Gel	diazepam	5 mg/mL, 4mL pre- filled syringe	020648	1	2008-12-08
DIASTAT ACUDIAL	Rectal Gel	diazepam	2.5 mg/0.5 mL 5 mg/mL 10 mg/2 mL 15 mg/3 mL 20 mg/4 mL	020648	1	2004-03-23

US Patents and Regulatory Information for diazepam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	VALRELEASE	diazepam	CAPSULE, EXTENDED RELEASE;ORAL	018179-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Chartwell Molecular	DIAZEPAM	diazepam	CONCENTRATE;ORAL	204433-001	Apr 14, 2014	AA	RX	No	No
Hikma	DIAZEPAM INTENSOL	diazepam	CONCENTRATE;ORAL	071415-001	Apr 3, 1987	AA	RX	No	Yes
Bausch	DIASTAT	diazepam	GEL;RECTAL	020648-001	Jul 29, 1997	AB	RX	Yes	Yes
Bausch	DIASTAT	diazepam	GEL;RECTAL	020648-002	Jul 29, 1997		DISCN	Yes	No
Bausch	DIASTAT	diazepam	GEL;RECTAL	020648-003	Jul 29, 1997		DISCN	Yes	No
Bausch	DIASTAT	diazepam	GEL;RECTAL	020648-004	Jul 29, 1997		DISCN	Yes	No

Expired US Patents for diazepam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	DIASTAT	diazepam	GEL;RECTAL	020648-003	Jul 29, 1997
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-002	Jan 10, 2020
Bausch	DIASTAT	diazepam	GEL;RECTAL	020648-005	Jul 29, 1997
Bausch	DIASTAT ACUDIAL	diazepam	GEL;RECTAL	020648-007	Sep 15, 2005
Roche	VALRELEASE	diazepam	CAPSULE, EXTENDED RELEASE;ORAL	018179-001	Approved Prior to Jan 1, 1982
Bausch	DIASTAT	diazepam	GEL;RECTAL	020648-004	Jul 29, 1997
Roche	VALIUM	diazepam	INJECTABLE;INJECTION	016087-001	Approved Prior to Jan 1, 1982

International Patents for diazepam

Country	Patent Number	Title	Estimated Expiration
China	107737100	苯二氮卓组合物的投与 (Administration of benzodiazepine)
World Intellectual Property Organization (WIPO)	2009121039
European Patent Office	4085899	ADMINISTRATION DE BENZODIAZÉPINE (ADMINISTRATION OF BENZODIAZEPINE)
Japan	2011516425	ベンゾジアゼピン組成物の投与
Japan	6883918
China	103796656	Administration of benzodiazepine
Australia	2022290861	METHODS AND COMPOSITIONS FOR TREATING SEIZURE DISORDERS IN PEDIATRIC PATIENTS

Diazepam: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Diazepam, a benzodiazepine first marketed in 1963 under the brand Valium, remains a globally significant pharmaceutical with applications in anxiety, muscle spasms, seizures, and alcohol withdrawal. Despite evolving medical practices and regulatory landscapes, diazepam maintains a substantial market presence, especially in developing regions. This analysis explores the current investment landscape, market drivers, competitive positioning, regulatory environment, and projected financial trends, providing insights for stakeholders assessing diazepam's long-term value.

---

What is the Current Market Landscape for Diazepam?

Market Size and Revenue Estimates

Year	Estimated Global Market Value (USD billions)	Compound Annual Growth Rate (CAGR)	Source
2022	$1.2	2.0% (projected)	[1], [2]
2023	$1.22	1.7%	[2]

Note: The market value includes all formulations—oral tablets, injectables, and rectal gels.

Geographical Distribution and Market Segments

Region	Market Share (%)	Key Drivers	Regulatory Status	Notable Trends
North America	40	High prevalence of anxiety and seizures	Strict regulations; generic penetration	Rising off-label use
Europe	20	Aging population, anxiety; prescription rates	Stringent controls; EMA oversight	Shift toward alternative therapies
Asia-Pacific	25	Increasing mental health awareness; lower costs	Less restrictive; increasing imports	Growing market, local manufacturing
Rest of World	15	Limited access to newer anxiolytics	Varies	Market expansion potential

Key Market Drivers

• Persistent Medical Need: Despite newer anxiolytics, diazepam persists due to cost-effectiveness and established efficacy.
• Off-label Uses: Employments in sedation during medical procedures and for acute anxiety episodes.
• Regulatory Shifts: Loosened regulations in emerging markets favor distribution expansion.

---

Market Dynamics Influencing Diazepam's Investment Outlook

Regulatory and Legal Framework

• FDA and EMA Regulations: Strict controls on benzodiazepines to prevent misuse (e.g., DEA classifications). Patent expirations have led to generic proliferation.
• Generic Market Entry: Over 100 generic manufacturers globally; increased competition exerts downward pressure on prices.
• Distribution Controls: Prescription-only status in most jurisdictions, but diversion risks influence regulatory adjustments.

Medical and Clinical Trends

• Replacement by Novel Agents: Rise of SSRIs and SNRI antidepressants, and newer anxiolytics like pregabalin.
• Guideline Recommendations: Limited positioning for diazepam in current clinical guidelines [3].
• Off-label and Emergency Use: Maintained in some regions for procedural sedation and status epilepticus.

Market Challenges and Opportunities

Challenges	Opportunities
Declining brand usage in developed markets	Expansion in low-income countries with high unmet needs
Growing concerns about dependency and misuse	Development of abuse-deterrent formulations
Competition from newer, safer drugs	Potential for repurposing or new formulation strategies

Competitive and Patent Landscape

Aspect	Status	Notes
Patent Protections	Nearly expired	Limited exclusivity in most regions
Patent Litigation	Occasional legal actions over formulations	Generally low impact due to expired patents

---

Financial Trajectory: Revenue, Cost, and Profitability Analysis

Revenue Forecast (2023–2030)

Year	Estimated Revenue (USD billions)	CAGR	Assumptions
2023	$1.22	-	Baseline year
2024	$1.25	2.5%	Slight market growth
2025	$1.28	2.4%	Steady demand in emerging markets
2026	$1.31	2.3%	Continued expansion
2027	$1.34	2.2%	Market saturation in mature regions
2028	$1.36	1.8%	Stabilization
2029	$1.37	0.7%	Market plateau
2030	$1.38	0.4%	Market maturity

Cost Structure and Margins

• Manufacturing Costs: Approx. 20–25% of revenue, with scale efficiencies.
• Regulatory Compliance: Additional costs for strict controls, approximately 5–8%.
• R&D: Low, as diazepam is off-patent; focus on formulation improvements.

Profitability Metrics	2023 Est.	Notes
Gross Margin	60–65%	Generic competition maintains low prices
Operating Margin	15–20%	Regulatory costs and distribution influence margins
Net Margin	10–15%	Stable, barring legal or regulatory shifts

Investment Scenarios

Scenario	Outlook	Key Factors	Implication
Optimistic	Moderate growth in emerging markets; new formulations	Market expansion, minimal regulatory hurdles	Steady revenue increase, attractive returns
Neutral	Market stabilization; decline in mature regions	Marginal growth, patent expiries	Limited upside, focus on cost management
Pessimistic	Regulatory tightening or substitution by newer drugs	Stricter controls, declining off-label use	Revenue declines, divestment considerations

---

Comparison with Similar Benzodiazepines

Drug	Market Share (%)	Approved Uses	Patent Status	Key Market Dynamics
Diazepam	60	Anxiety, seizures, muscle spasms	Expired, generic dominant	Volume-based sales, low margins
Lorazepam	20	Anxiety, pre-anesthesia	Recently expired	Targeted for specific indications
Alprazolam	15	Anxiety, panic disorders	Active patents until ~2024	Strong brand presence, abuse concerns
Others	5	Various	Varies	Niche markets

---

Regulatory Policies Impacting Diazepam Investment

• US: DEA Schedule IV classification, strict prescription regulations; increasing scrutiny over misuse.
• Europe: Managed by EMA; controlled distribution, potential for tighter controls depending on misuse statistics.
• Emerging Markets: Generally less restrictive; higher risks of diversion but increased access.

Policy Trends

• Enhanced monitoring and prescription tracking.
• Efforts to curb abuse may restrict availability.
• Potential de-listing of benzodiazepines in formularies due to dependency concerns.

---

Concluding Financial Outlook

While diazepam faces challenges from regulatory scrutiny, competitive generic markets, and evolving treatment standards, its entrenched role in emergency and hospital settings sustains a baseline revenue stream. Long-term growth prospects hinge on expansion into emerging markets, potential reformulation to address abuse liabilities, and strategic positioning against newer therapies.

---

Key Takeaways

• Market Stability in Emerging Regions: Significant growth opportunities exist in Asia-Pacific and Africa due to unmet needs.
• Regulatory Risks Dominate: Policymaker concerns over dependency and diversion influence future sales trajectories.
• Generic Competition Limits Margins: The absence of patent protections results in price erosion.
• Potential for Formulation Innovation: Abuse-deterrent formulations could open niche markets.
• Financial Growth Outlook: Modest CAGR (~1.8–2.5%) projected through 2030, driven primarily by volume rather than price increases.

---

FAQs

1. Will diazepam maintain its market relevance amid newer anxiolytics?

Yes. Despite the rise of alternatives like SSRIs, diazepam's ease of access, low cost, and emergency use keep it relevant, especially in resource-limited settings.

2. How do patent expiries affect diazepam investment prospects?

Patent expiries facilitate massive generic entry, pressuring prices downward but also expanding market access. Investment opportunities may shift toward formulations with abuse-deterrent features or niche indications.

3. What regulatory trends could impact diazepam’s market in the coming years?

Increased controls on prescription and distribution, efforts to prevent misuse, and potential reclassification could reduce geographic availability, impacting revenues.

4. Are new formulations of diazepam a viable investment avenue?

Potentially. Abuse-deterrent formulations or controlled-release versions could command premiums and open new markets, though development costs are significant.

5. How does diazepam compete with newer therapies for seizure and anxiety management?

In certain applications, especially acute care and emergency settings, diazepam remains preferred. For long-term management, newer agents may supplant it, impacting sales in outpatient markets.

---

References

[1] MarketResearch.com, "Global Benzodiazepine Market Forecast," 2022
[2] IMS Health, "Pharmaceutical Market Data," 2023
[3] NICE Guidelines, "Management of Anxiety and Depression," 2021